Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Phase II trial of carboplatin in patients with advanced germ-cell testicular tumors and transitional cell carcinomas of the urinary tract

  • 23 Accesses

  • 8 Citations

Summary

Carboplatin, an analog of cisplatin, was evaluated in a phase II study involving 25 patients with advanced testicular tumor and 45 with transitional cell carcinoma (TCC) of the urinary tract; 21 and 38 cases, respectively, were evaluable for response. Prior treatment with cisplatin-based chemotherapy had occurred in 7 of the testicular cancer patients and in 11 with TCC. The response rate (complete + partial response) in testicular tumors was 47.6%. The best response rate was observed in seminomas (70.0%), whereas the response rate in nonseminomas was 27.3%. The seminoma patients had mainly stage IIIA or less than IIA disease, with metastatic lesions restricted to the lymph nodes. Three responses were seen in patients previously treated with cisplatin. In TCC, the response rate was 18.4%. Good-risk patients were treated with a dose of 400 mg/m2 every 4 weeks, whereas poor-risk patients received a lower dose of 300 mg/m2. The response rates for good-risk patients were 50.0% in testicular lesions and 26.1% in TCC. For poor-risk patients, the response rates were 40.0% and 6.7%, respectively. Carboplatin was well tolerated, with no significant renal impairment or ototoxicity detected. Nausea and vomiting were experienced by 51.7% of patients, but the severity was low; half of these patients demonstrated WHO grade I toxicity. However, myelosuppression was severe. In conclusion, carboplatin demonstrated activity in both testicular tumors and TCC and is worthy of further study, especially in combination with other active drugs.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Canetta R, Franks C, Smaldone L, Bragman K, Rozencweig M (1986) Single agent activity of carboplatin. Proceedings of the 5th NCI, EORTC Symposium on New Drugs in Cancer Therapy, October, 1986, Amsterdam

  2. 2.

    Einhorn LH, Williams SD (1980) The management of disseminated testicular cancer. In: Einhorn LH (ed) Testicular tumors: management and treatment. Masson, New York, pp 117–149

  3. 3.

    Koyama Y (1985) Response criteria for the chemotherapy of solid tumors. In: Saito T (ed) Development of anticancer drugs and response criteria. Realize Inc., Tokyo, pp 115–127

  4. 4.

    Motzer RJ, Bosl GJ, Tauer K, Golbey R (1987) Phase II trial of carboplatin in patients with advanced germ cell tumors refractory to cisplatin. Cancer Treat Rep 71: 197–198

  5. 5.

    Ogawa M, Imajo K, Horikoshi N, Inoue K, Mukaiyama T, Yamajaki H, Ueno K, Nakamura T, Aiba K, Kuraishi Y (1987) A phase I study of carboplatin. Jpn J Cancer Chemother 14: 1292–1296

  6. 6.

    Oliver RTD, Kwok HK, Highman WJ, Waxman J (1986) Methotrexate, cisplatin and carboplatin as single agents and in combination for metastatic bladder cancer. Br J Urol 58: 31–35

  7. 7.

    Ozols RF, Ostchega Y, Curt G, Young RC (1987) High dose carboplatin in refractory ovarian cancer patients. J Clin Oncol 5: 197–201

  8. 8.

    Peckham MJ, Horwich A, Brada M, Drury A, Hendry WF (1985) cis-Diammine-1, 1-cyclobutane dicarboxylate platinum II (carboplatin) in the treatment of testicular germ-cell tumors: a preliminary report. Cancer Treat Rev 12 (Suppl A): 101–110

  9. 9.

    Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC, Morse MJ, Whitmore WF (1985) Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133: 403–407

  10. 10.

    Trump DL, Elson P, Brodovsky H, Vogl SE (1987) Carboplatin in advanced, refractory germ cell neoplasms: a phase II Eastern Cooperative Oncology Group study. Cancer Treat Rep 71: 989–990

  11. 11.

    Wasserman TH, (1975) Tabular analysis of the clinical chemotherapy of solid tumors. Cancer Chemother Rep Part 3 62: 399–419

  12. 12.

    WHO handbook for reporting results of cancer treatment (1979) WHO offset publication 48. WHO, Geneva

Download references

Author information

Correspondence to Hideyuki Akaza.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Akaza, H., Hagiwara, M., Deguchi, N. et al. Phase II trial of carboplatin in patients with advanced germ-cell testicular tumors and transitional cell carcinomas of the urinary tract. Cancer Chemother. Pharmacol. 23, 181–185 (1989). https://doi.org/10.1007/BF00267952

Download citation

Keywords

  • Urinary Tract
  • Carboplatin
  • Renal Impairment
  • Metastatic Lesion
  • Stage IIIA